June 5th 2023
A key opinion leader in breast cancer management shares insight on the treatment armamentarium for patients with HER2+ disease.
March 16th 2023
Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.
March 10th 2023
Virginia Kaklamani, MD, discusses the utilization of elacestrant following treatment with CDK4/6 inhibitors in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.
March 9th 2023
Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.
Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.
March 7th 2023
Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.
March 2nd 2023
Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.
A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.
February 28th 2023
Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.
Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.
February 23rd 2023
Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.
Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.
February 22nd 2023
Virginia Kaklamani, MD, discusses how racial disparities may affect patient outcomes and treatment expectations based on data from the RxPONDER trial in breast cancer.
February 21st 2023
Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.
Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.
February 16th 2023
A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.
Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.
February 9th 2023
A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.
Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.
December 22nd 2022
Virginia Kaklamani, MD reviews updated results and clinical implications of the phase 3 EMERALD trial evaluating elacestrant in patients with ER+/HER2- metastatic breast cancer presented at the 2022 San Antonio Breast Cancer Symposium.